Edmond DE Rothschild Holding S.A. Buys New Position in Teva Pharmaceutical Industries Ltd. $TEVA

Edmond DE Rothschild Holding S.A. bought a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 41,153 shares of the company’s stock, valued at approximately $1,648,000.

Other hedge funds also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Teva Pharmaceutical Industries by 1.3% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company’s stock worth $1,561,120,000 after acquiring an additional 500,000 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Teva Pharmaceutical Industries by 5.8% in the 2nd quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after purchasing an additional 419,329 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Teva Pharmaceutical Industries by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after purchasing an additional 72,880 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Teva Pharmaceutical Industries by 128.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock valued at $103,538,000 after purchasing an additional 1,716,315 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,864,594 shares of the company’s stock valued at $86,240,000 after purchasing an additional 73,410 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Brian Savage sold 7,342 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. This represents a 46.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 715,945 shares of company stock valued at $29,061,351. 0.54% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on TEVA shares. Leerink Partners boosted their target price on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. UBS Group lifted their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. TD Cowen lifted their price target on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Finally, Argus upped their price objective on Teva Pharmaceutical Industries from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 17th. Fourteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus target price of $48.64.

Read Our Latest Report on TEVA

Teva Pharmaceutical Industries News Summary

Here’s some of the latest news about TEVA:

  • Positive Sentiment: Zacks Research moved its rating from “strong sell” to “hold.” Barclays also raised its price target to $50 from $47 and maintained an “overweight” rating, signaling analysts see potential upside. Read rating information
  • Negative Sentiment: Investors remain focused on the departure of Global R&D chief and Chief Medical Officer Eric Hughes, which previously prompted a sharp stock decline. Teva says its strategy, R&D priorities and expectations are unchanged, and it is searching for a successor, but leadership uncertainty may weigh on sentiment. Read announcement
  • Negative Sentiment: A notice from investor-law firm SueWallSt says it is investigating potential claims related to the decline following Hughes’s departure. This is an investigation notice, not a finding of wrongdoing, but it adds a potential legal overhang. Read notice

Teva Pharmaceutical Industries Stock Up 1.8%

Teva Pharmaceutical Industries stock opened at $39.23 on Friday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $24.01 and a fifty-two week high of $44.57. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. The company has a market capitalization of $45.71 billion, a P/E ratio of 91.23, a PEG ratio of 3.40 and a beta of 0.97. The stock has a 50-day simple moving average of $40.60 and a 200-day simple moving average of $35.24.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The firm had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.78 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

(Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Read More

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.